Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra, Feinstein Institute for Medical Research, Lake Success, NY.
Divisions of Hematology and Medical Oncology, Stanford Cancer Institute, Stanford, CA.
JCO Oncol Pract. 2023 Mar;19(3):107-115. doi: 10.1200/OP.22.00226. Epub 2022 Nov 21.
Recent data support incorporation of immune checkpoint inhibitors into the treatment armamentarium for esophageal, gastroesophageal junction, and gastric (esophagogastric) cancer. This practical review focuses on clinical trials that influenced US Food and Drug Administration approvals and treatment guidelines in esophagogastric cancer, including the impact of location, stage, histology, human epidermal growth factor receptor 2 status, and PD-(L)1 expression on these guidelines. The role of immunotherapy in the locally advanced and metastatic setting is constantly expanding. Over the next few years, the many ongoing trials exploring immunotherapy are anticipated to bring new treatment regimens into the frontline setting with the potential to improve survival in patients with advanced disease.
最近的数据支持将免疫检查点抑制剂纳入食管癌、胃食管交界处癌和胃癌（胃食管）的治疗方案中。本实践综述重点介绍了影响美国食品和药物管理局批准和治疗胃食管癌症指南的临床试验，包括位置、阶段、组织学、人表皮生长因子受体 2 状态和 PD-（L）1 表达对这些指南的影响。免疫疗法在局部晚期和转移性疾病中的作用正在不断扩大。在未来几年，许多正在进行的免疫疗法试验预计将为晚期疾病患者带来新的治疗方案，有可能提高他们的生存机会。
